

Using Continuous Glucose Monitors in Bariatric Surgical Patients: A Surprised Finding

Peter S Billing MD FACS FASMBS Transform Health Partners Transform Weight Loss IFSO 2024

Disclosures


- Consultant for Medtronic
- Founder of Transform Weight Loss
- Partner Transform Health Partners
- Partner Pearl SurgiCenter


Continuous Glucose Meters (CGMs)

- Dexcom G7
- Signos
- Libre
- Eversense (Senseonics or Ascenscia)



Eversense CGM





Background

- Gastric bypass patients can develop symptomatic hypoglycemia.
- Dietary change with high protein diet is recommending along with increasing frequency of small meals.
- Hypoglycemia may lead to weight regain and sugar cravings.
- Many RY gastric bypass patients cannot receive coverage for GLP1RA due to not having a Type 2 diabetes diagnosis.
- CGMs can help provide diagnostic evidence of symptomatic hypoglycemia or type 2 diabetes.

American Diabetes Association Defining type 2 diabetes

- Random (also called Casual) Plasma Glucose Test
- This test is a blood check at any time of the day when you have severe diabetes symptoms.
- Diabetes is diagnosed at blood glucose of greater than or equal to 200 mg/dl

https://diabetes.org/about-diabetes/diagnosis

Study

- Retrospective
- N=4
- All patients had gastric bypass.
- Patients had daily symptomatic hypoglycemia to below 50 fasting.
- CGM data also showed glucose over 200 mg/dL 30-60 minutes after eating. Subsequent hypoglycemia is seen.
- This resolves with GLP1RA treatment.
- High protein diets were recommended.
- Small frequent meals.

Case report#1: Patient with RYGB in 2000


| 16:15 .ul 중 988 ∢ Search | | | | |
|---|--------|--------------|--------|------------|
| Glucose Within Target Levels | | | | |
| Reports | | | | Ċ |
| 1 Day | 7 Days | Days 14 Days | | s 90 Days |
| Glucose Statistics (mg/dL) (Dec 17, 2022 - Mar 17, 2023) | | | | |
| Perio | d Av | g. Lov | w High | Std Dev |
| 0 - 6 | 10 | 2 45 | 5 171 | 13.4 |
| 6 - 12 | : 11 | 2 59 | 220 | 21.2 |
| 12 - 18 | 3 12 | 21 56 | 268 | 28.3 |
| 18 - 0 |) 11 | 4 49 | 212 | 22.1 |
| ALL | 11 | 3 45 | 268 | 23.1 |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |


- A1c 4.7.
- BMI 20.
- CGM data 90 days pre GLP1 treatment Jan-March 2023.
- Glucose down to 45.
- Glucose up to 268 after eating.
- Daily sugar cravings.


Case report #2

- 45-year-old male who had RY gastric bypass in 2021.
- Lowest weight 180 lbs. in 2022. Preop weight 260 lbs.
- Weight of 220 lbs. BMI 32.9. March 2024. 40 lbs. regain.
- A1c 6.1. Fasting glucose 48.
- Symptomatic hypoglycemia
- CGM data from April 1- May 31st 2024 shows hypo and hyperglycemia
- GLP1 medication provided with improvement of hypo and hyperglycemia.

Week 1: hypoglycemia/hyperglycemia








After several months GLP1RA treatment

This graph shows your data averaged over 14 days



Conclusions

- CGMs can help patients get coverage for GLP1 medications by diagnosing Type 2 diabetes in gastric bypass patients in patients with normal A1c and fasting glucose.
- GLP1s improve glycemic control and mitigate symptomatic hypoglycemia.
- Any patient with weight regain or hypoglycemia after gastric bypass should be given a CGM and started on a GLP1RA.